Sector Expert: Marcel Wijma

The Daily Molecule (Van Leeuwenhoeck Research) , Van Leeuwenhoeck Research

Image: Marcel Wijma

Marcel Wijma is founder and managing director of Van Leeuwenhoeck Inc. (VLI). VLI is actively engaged in the financial research of life sciences companies in Europe, North America and Australia. VLI provides institutional investors and other professional investors with independent, unbiased research on the real value of innovative life sciences companies. In 2009, Wijma was named one of the top three biotech analysts in Europe by the Financial Times/Starmine. He leads the professional VLR research team, which is augmented by selected external financial researchers with a specialization in life sciences. Wijma has a master's degree in financial economics from Erasmus University in Rotterdam.

Subscribe to
Streetwise Reports

Companies Commented On



Recent Interviews

Circling the Globe for Uncommon Biotech Opportunities: Van Leeuwenhoeck's Marcel Wijma (2/17/16)
worldhealth630

Stock analysts fall into a few different categories. There are buyside analysts and sellside analysts, and then there are independent analysts commissioned by companies to highlight underexposed business models and growth prospects. The independent analyst, such as Van Leeuwenhoeck's Marcel Wijma, normally works in the small- and micro-cap stock universe, where the buyside and sellside rarely go. In this interview with The Life Sciences Report, Wijma brings to light five diverse, overlooked small-cap biotech stocks from Canada, Europe and Australia that could bring huge returns to investor portfolios.

Probe Biotech's Diverse Subsectors for Undervalued Companies: Van Leeuwenhoeck's Marcel Wijma (7/1/15)
flasks580

The life sciences industry is evolving rapidly. Many say it's at the beginning of an explosive growth stage that will see the development and commercialization of novel therapeutics and diagnostics still being imagined in scientific laboratories today. This explosion of innovation also means an explosion of investment opportunity. In this interview with The Life Sciences Report, Marcel Wijma, chief research analyst at Van Leeuwenhoeck Institute, explores some smaller companies working on the industry's forefront.

Recent Quotes

"With a successful Phase III trial and considering the market potential for RVX-208, a very significant upside potential for RVX-208 and RVX is attainable."

— Marcel Wijma, Van Leeuwenhoeck Research (5/11/16)
more >

"RVX's strategy is to start with the clinical trial, derive data, and create value to increase the likelihood of a partnership deal with a large pharmaceutical company."

The Life Sciences Report Interview with Marcel Wijma (2/17/16)
more >

"RGS could be Australia's second success story in the stem cell industry."

The Life Sciences Report Interview with Marcel Wijma (2/17/16)
more >

"Results of MSB's Phase 2 diabetes trial have been published online."

— Marcel Wijma, The Daily Molecule (Van Leeuwenhoeck Research) (7/24/15)
more >

"RVX may have the answer to developing a new generation of cardio drugs."

The Life Sciences Report Interview with Marcel Wijma (7/1/15)
more >

"We believe RGS has the potential to become Australia's next success story in regenerative medicine."

The Life Sciences Report Interview with Marcel Wijma (7/1/15)
more >

"RGS is gravely undervalued at its current share price."

— Marcel Wijma, The Daily Molecule (Van Leeuwenhoeck Research) (4/23/15)
more >

"RVX, which is substantially undervalued, has an attainable and very significant upside potential."

— Marcel Wijma, Van Leeuwenhoeck Research (3/16/15)
more >



Due to permission requirements, not all quotes are shown.